Abivax Presents Breakthrough Anti-Fibrotic Data for Obefazimod at ECCO 2026 Alongside Comprehensive Ulcerative Colitis Results
核心洞察
Abivax will present 22 scientific abstracts at ECCO 2026, including novel preclinical data showing obefazimod's first evidence of anti-fibrotic activity in inflammatory bowel disease (搜索) models.
The oral presentation addresses intestinal fibrosis (搜索), a major complication in Crohn's disease (搜索) that leads to strictures and often requires surgery, with no current efficacious anti-fibrotic treatments available.
Additional presentations will showcase subgroup analyses from Phase 3 ABTECT induction trials demonstrating obefazimod's clinical activity across diverse patient populations and favorable tolerability profile.
Abivax SA announced that 22 scientific abstracts evaluating obefazimod for inflammatory bowel disease (搜索) treatment will be presented at The European Crohn's and Colitis Organization's 21st Annual Congress in Stockholm, Sweden, February 18-21, 2026. The presentations include a groundbreaking oral presentation on obefazimod's anti-fibrotic properties, marking the first evidence of such activity in preclinical IBD models.
Novel Anti-Fibrotic Activity Addresses Critical Unmet Need
The oral presentation scheduled for Saturday, February 21, 2026, titled "Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease (搜索)," will disclose new preclinical data addressing intestinal fibrosis (搜索), a serious complication particularly in Crohn's disease (搜索) patients. Fibrosis, characterized by excessive scar tissue formation, can lead to strictures that narrow the intestine and often necessitate surgical intervention. Currently, no efficacious anti-fibrotic treatment exists for IBD patients.
The preclinical study assessed obefazimod's anti-fibrotic effects using an in vitro fibrosis model with human small-intestinal fibroblasts and an in vivo TNBS-colitis mouse model. Prof. Silvio Danese, Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San Raffaele Hospital, will present these findings during the oral presentation session.
Comprehensive Clinical Data from Phase 3 ABTECT Trials
The accepted abstracts include one oral presentation, five digital oral presentations, and 16 posters reflecting an expanding dataset for obefazimod. The presentations feature subgroup analyses from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (搜索), demonstrating obefazimod's clinical activity across diverse patient subpopulations.
The data illustrates downregulation of pro-inflammatory cytokines, specifically IL-17A and IL-6, and highlights early symptomatic improvement along with other clinically meaningful benefits. The presentations will also reinforce obefazimod's favorable tolerability profile across various patient demographics and disease characteristics.
Clinical Significance and Market Impact
Marc de Garidel, Chief Executive Officer of Abivax, emphasized the significance of the comprehensive data presentation: "We are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress, highlighting the impactful and robust data we have generated in inflammatory bowel disease (搜索). Presenting a total of 22 abstracts highlights the increasing depth of clinical understanding we have gained from the ABTECT Induction Trials in ulcerative colitis (搜索)."
Dr. Fabio Cataldi, Chief Medical Officer of Abivax, added context about the clinical importance: "Intestinal fibrosis (搜索) is a major complication of Crohn's disease (搜索) that is not fully addressed by current therapies. This often leads to debilitating symptoms and the need for resection surgery. We look forward to sharing these new insights on obefazimod's anti-fibrotic properties, alongside the expansive clinical data to demonstrate obefazimod's potential efficacy and favorable safety profile in ulcerative colitis (搜索)."
Mechanism of Action and Therapeutic Potential
Obefazimod (ABX464) is an oral, first-in-class small molecule that selectively enhances miR-124 (搜索) expression in immune cells. The drug has demonstrated a favorable safety profile and potent anti-inflammatory effects across preclinical studies and Phase IIa and Phase IIb induction trials for ulcerative colitis (搜索). Its mechanism of action is distinct because it markedly increases miR-124 production, a unique RNA-splicing product with anti-inflammatory properties.
Clinical evidence indicates that obefazimod may help patients achieve remission and promote healing of inflammatory lesions associated with ulcerative colitis (搜索). The drug's ability to enhance miR-124 (搜索) expression in blood and colon tissue while reducing IL-17A and IL-6 in serum represents a novel approach to IBD treatment.
Broader Treatment Landscape Context
The ulcerative colitis (搜索) therapeutic landscape has broadened considerably with recent approvals of newer agents, including TREMFYA (guselkumab), SKYRIZI (risankizumab), VELSIPITY (etrasimod), and OMVOH (mirikizumab), demonstrating a shift toward more targeted biologics and innovative oral therapies. Despite these advances, safety remains a major limitation in ulcerative colitis management, with many patients requiring multiple lines of treatment.
The anticipated launch of emerging therapies including obefazimod, along with tulisokibart (Merck (搜索)), Afimkibart (搜索) (Roche), and MORF-057 (Eli Lilly), is expected to transform the ulcerative colitis (搜索) market landscape. These cutting-edge therapies are poised to offer new standards of care and unlock opportunities for medical innovation as they continue to mature and gain regulatory approval.